Jeune Aesthetics, a subsidiary of Krystal Biotech (NASDAQ: KRYS), announced results from its Phase 1 study of KB304 for treating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE